Childhood Central Nervous System Germ Cell Tumor
📧 Sign up to get email alerts when something new happens for Childhood Central Nervous System Germ Cell Tumor.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2014-07-09Clinical Trial Update: ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors [Phase 1]
A Phase 1 trial evaluating veliparib (ABT-888) in combination with temozolomide for pediatric patients with recurrent or refractory CNS tumo…
-
CLINICAL_TRIALS trial_result · 2014-01-28Clinical Trial Update: Sunitinib in Treating Young Patients With Refractory Solid Tumors [Phase 1]
A Phase 1 trial evaluating sunitinib in pediatric patients with refractory solid tumors, including various childhood central nervous system …
-
CLINICAL_TRIALS trial_result · 2013-09-30Clinical Trial Update: Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment [Phase 1]
Phase 1 study of pazopanib hydrochloride in pediatric patients with relapsed or treatment-refractory solid tumors has completed, reporting o…
-
CLINICAL_TRIALS trial_result · 2013-07-02Clinical Trial Update: Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma [Phase 1]
This phase 1 trial assessed safety and preliminary activity of the HDAC inhibitor vorinostat combined with bortezomib in pediatric patients …
-
CLINICAL_TRIALS trial_result · 2013-06-05Clinical Trial Update: Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas [Phase 1]
Phase 1 study of oxaliplatin with irinotecan in pediatric patients with refractory solid tumors or lymphomas has been completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2013-01-16Clinical Trial Update: Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma [Phase 1]
Phase 1 trial of ispinesib in young patients with relapsed or refractory solid tumors and lymphoma has completed.